Among patients with heart failure with preserved ejection fraction (HFpEF), lower versus higher ranges of EF signal fundamentally different morphologies and hemodynamic responses, which may have ...
S.A Decker Weiss, NMD, FASA, PLC A complex ischemic cardiomyopathy case exploring myocardial recovery through ...
An overview of the PARAGON-HF trial with special consideration to the rationale behind the design, the cardiovascular end points, and the safety profile. John McMurray, MBChB: The most recent attempt ...
Expert physicians consider how the treatment of patients differ when they have HFpEF versus HFrEF. Scott D. Solomon, MD: When we think about the standard care in heart failure, we have to make the ...
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ...
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart ...
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results